Human CD44v9 Protein
Catalog No: CD44V9-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human CD44v9 Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Gln21-Pro220 & Gln506-Ser534 (UniProt accession: P16070-1).
Product Details
- Molecular Aliases
- CD44; CDw44; Epican; ECMR-III; LHR; MDU2; MDU3; MIC4; PGP-I; CSPG8; HCELL; HUTCH-I; IN; MC56
- Protein Length
- Gln21-Pro220
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 51.17 kDa. Due to glycosylation, the protein migrates to 80-100 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 0.1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
- State
- Liquid
- Storage Conditions
- Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Data Display
Human CD44v9 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human CD44v9 is greater than 95% as determined by SEC-HPLC.
Immobilized Human CD44v9, hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-CD44v9 Antibody, hFc Avi tag with the EC50 of 13.1ng/ml determined by ELISA. (QC Test)
Background
CD44 is a hyaluronan binding cell surface signal transducing receptor that influences motility, cell survival and proliferation as well as the formation of tumor microenvironment. CD44 contains two variable regions encoded by variable exons. Alternative splicing, which is often deregulated in cancer, can produce various isoforms of CD44 with properties that may have different tissue specific effects and therefore even diverse effects on cancer progression
References
- Prochazka L, Tesarik R, Turanek J. Regulation of alternative splicing of CD44 in cancer. Cell Signal. 2014 Oct;26(10):2234-9. doi: 10.1016/j.cellsig.2014.07.011. Epub 2014 Jul
- PMID: 25025570.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.